Pharmaceutical Cocrystals of Pain Relieving Drugs
##semicolon##
Pharmaceutical cocrystal##common.commaListSeparator## Coformer##common.commaListSeparator## Active pharmaceutical ingredient (API)##common.commaListSeparator## Drug##common.commaListSeparator## NSAIDs.摘要
Cocrystallisation of two components into one crystal form can enhance the solid-state properties of drug compounds. Cocrystals are considered as the next generation modified-active pharmaceutical ingredients with improved physical-chemical, (aqueous solubility, dissolution, hygroscopicity, bioavailability, stability, increase of melting point, purity of an active pharmaceutical ingredients (API), intellectual property positions) and pharmacokinetic properties. Cocrystal formation may overcome dissolution problems of highly lipophilic APIs because the new crystalline lattice being formed often has very different dissolution properties compared to those of the crystals of the API alone. In this review article, pharmaceutical cocrystals of pain relieving drugs (NSAIDs, acetaminophen and opioids) are reported. The co-crystallization of active pharmaceutical ingredients (APIs) with non-toxic co-formers or other API as conformer has been shown to increase the solubility, stability, bioavailability of APIs, and improved tablet ability. Keywords: Pharmaceutical cocrystal, coformer, active pharmaceutical ingredient (API), drug, NSAIDs
出版日期
期號
分類
授權條款
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
· I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
· I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
· I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
· I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
_______________
We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
